1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Hester Biosciences Limited

Hester Biosciences Limited

HESTERBIO.BO
Hester Biosciences LimitedIN flagBombay Stock Exchange
1,940.00
INR
-82.15
- -
16.50BMarket Cap

Total Valuation

Hester Biosciences Limited carries a market capitalization of 16.50B, placing it among publicly traded companies globally. Its enterprise value stands at 12.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap16.50B
Enterprise Value12.13B

Share Statistics

Hester Biosciences Limited currently has 8.51M shares outstanding.

Shares Outstanding8.51M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Hester Biosciences Limited trades at a trailing price-to-earnings ratio of 18.66. The price-to-sales ratio is 3.12, and the price-to-book ratio stands at 122.05.

PE Ratio18.66
PS Ratio3.12
PB Ratio122.05
P/TBV Ratio2.90
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Hester Biosciences Limited trades at an EV/EBITDA multiple of 17.90 and an EV/FCF ratio of 146.37. The EV/Sales ratio of 3.65 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.90 provides insight into valuation relative to core operating earnings.

EV / Sales3.65
EV / EBITDA17.90
EV / EBIT17.90
EV / FCF146.37

Financial Position

Hester Biosciences Limited maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 52.96, indicating elevated leverage, while an interest coverage ratio of 6.20 demonstrates adequate ability to service its debt obligations.

Current Ratio1.37
Quick Ratio0.18
Debt / Equity52.96
Debt / EBITDA2.87
Interest Coverage6.20

Financial Efficiency

Hester Biosciences Limited posts a return on equity of 654.03 and a return on invested capital of 9.07.

Return on Equity (ROE)654.03
Return on Assets (ROA)8.22
Return on Invested Capital (ROIC)9.07
Return on Capital Employed (ROCE)27.83
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.18

Taxes

Over the trailing twelve months, Hester Biosciences Limited has paid 183.52M in income taxes, reflecting an effective tax rate of 24.20.

Income Tax183.52M
Effective Tax Rate24.20

Stock Price Statistics

Hester Biosciences Limited's stock has gained approximately 9.05616% over the past 52 weeks. The 50-day moving average sits at 1,603.19, while the 200-day moving average is 1,665.09.

Beta (5Y)N/A
52-Week Price Change9.05616%
50-Day Moving Average1,603.19
200-Day Moving Average1,665.09
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Hester Biosciences Limited generated 3.33B in revenue and converted that into 556.38M in net income, yielding earnings per share of 69.91. EBITDA reached 677.76M, while operating income came in at 677.76M.

Revenue3.33B
Gross Profit2.51B
Operating Income677.76M
Pretax Income758.35M
Net Income556.38M
EBITDA677.76M
EBIT677.76M
Earnings Per Share (EPS)69.91

Balance Sheet

Hester Biosciences Limited holds 274.90M in cash and equivalents against 1.95B in total debt, resulting in a net debt position of 1.85B. Total book value stands at 85.07M, with working capital of 560.84M providing operational flexibility.

Cash & Cash Equivalents274.90M
Total Debt1.95B
Net Debt1.85B
Equity (Book Value)85.07M
Book Value Per Share10.35
Working Capital560.84M

Margins

Hester Biosciences Limited operates with a gross margin of 75.36, reflecting its pricing power and cost economics. The operating margin of 20.38 and net profit margin of 16.73 provide insight into operational efficiency.

Gross Margin75.36
Operating Margin20.38
Pretax Margin22.80
Profit Margin16.73
EBITDA Margin20.38

Stock Splits

Hester Biosciences Limited's most recent stock split took place on September 27, 2012 with a 2:3 split ratio.

Last Split Date9/27/2012
Split Ratio2:3

Scores

Hester Biosciences Limited posts an Altman Z-Score of 2.94, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.94